Category Archives: Healthcare

How Engineered Living Therapeutics Are Redefining Healthcare

The Living Cure

LAST UPDATED: January 29, 2026 at 5:38 PM

How Engineered Living Therapeutics Are Redefining Healthcare

GUEST POST from Art Inteligencia

For centuries, medicine has been about chemistry — pills and potions designed to intervene in biological processes. But what if the medicine itself could think? What if it could adapt? What if it was alive? This isn’t science fiction; it’s the audacious promise of Engineered Living Therapeutics (ELTs), and it represents a paradigm shift in human-centered healthcare that will redefine our relationship with illness.

As a thought leader in human-centered change and innovation, I’ve seen countless industries disrupted by radical new approaches. Biotechnology is no exception. ELTs are not merely advanced drugs; they are biological systems, often engineered microbes or cells, programmed to perform specific therapeutic functions within the body. This is innovation at its most profound: leveraging the inherent intelligence and adaptability of life itself to heal.

Beyond the Pill: The Intelligence of Living Medicine

Traditional pharmaceuticals often act as blunt instruments, targeting specific pathways with limited specificity and potential side effects. ELTs, by contrast, offer a level of precision and dynamic response previously unimaginable. Imagine a therapy that can detect disease markers, produce therapeutic compounds only when needed, or even self-regulate its activity based on the body’s changing state. This intelligent adaptability is what makes ELTs a truly human-centered approach to healing, tailoring treatment to the unique, fluctuating biology of each individual.

“The future of medicine isn’t just about what we put into the body; it’s about what we awaken within it. Engineered Living Therapeutics aren’t just treatments; they’re collaborations with our own biology.”

— Braden Kelley

Case Study I: Reprogramming the Gut for Metabolic Health

A burgeoning area for ELTs lies within the human microbiome. Consider the challenge of chronic metabolic diseases like Type 2 Diabetes. Current treatments often manage symptoms without addressing underlying dysregulation. One biotech startup engineered a strain of probiotic bacteria to reside in the gut. This engineered bacterium was programmed to sense elevated glucose levels and, in response, produce and deliver an insulin-sensitizing peptide directly within the intestinal lumen.

This targeted, localized intervention offered a novel way to manage blood sugar, reducing the systemic side effects associated with orally administered drugs. The innovation here wasn’t just a new molecule, but a living delivery system that dynamically responded to the body’s needs, representing a truly personalized and responsive therapy.

Case Study II: Targeted Oncology with “Smart” Cells

Cancer treatment remains one of medicine’s most formidable challenges. While CAR T-cell therapy has revolutionized certain hematological cancers, ELTs are pushing the boundaries further. Imagine immune cells engineered not only to identify cancer cells but also to produce potent anti-cancer molecules directly at the tumor site, or even to activate other immune cells to join the fight.

One research initiative is exploring tumor-infiltrating lymphocytes (TILs) engineered to express specific receptors that bind to unique tumor antigens and simultaneously secrete localized immunomodulators. This approach aims to overcome the immunosuppressive microenvironment of solid tumors, a significant hurdle for many current immunotherapies. This represents a leap towards truly precision oncology, where the body’s own defenders are given a sophisticated, living upgrade.

Leading the Charge: Companies and Startups in the ELT Space

The ELT landscape is rapidly evolving, attracting significant investment and groundbreaking research. Established pharmaceutical giants like Novartis and Gilead Sciences (through Kite Pharma) are already active in the approved CAR T-cell therapy space, which serves as a foundational ELT. However, a vibrant ecosystem of innovative startups is pushing the frontier. Companies like Seres Therapeutics are leading with microbiome-based ELTs for infectious diseases. Synlogic is developing engineered bacteria for metabolic disorders and cancer. Ginkgo Bioworks, while not a therapeutic company itself, is a critical enabler, providing the foundational synthetic biology platform for engineering organisms. Additionally, numerous academic spin-offs and smaller biotechs are emerging, focusing on niche applications, advanced gene editing techniques within living cells, and novel delivery mechanisms, signaling a diverse and competitive future for ELTs.

Designing Trust in Living Systems

ELTs raise questions about control, persistence, and governance. Human-centered change demands proactive transparency, ethical foresight, and adaptive regulation.

The future of ELTs will be shaped as much by trust as by technology.

The Human-Centered Future of Living Therapies

Healthcare innovation has long been constrained by an assumption that treatment must be static to be safe. Engineered Living Therapeutics (ELTs) challenge that assumption by embracing biology’s native strength: adaptability.

ELTs are living systems intentionally designed to operate inside the human body. They sense, decide, and respond. In doing so, they force leaders, regulators, and innovators to rethink what medicine is and how it should behave.

“True healthcare innovation begins when we stop trying to control biology and start designing with it.”

— Braden Kelley

The journey with ELTs is just beginning. As with any transformative technology, there are ethical considerations, regulatory hurdles, and manufacturing complexities to navigate. However, the potential for these living medicines to offer durable, highly targeted, and adaptive treatments for a vast array of diseases — from cancer and autoimmune disorders to infectious diseases and chronic conditions — is immense. By placing the human at the center of this innovation, ensuring patient safety, accessibility, and shared understanding, we can unlock a future where our biology becomes an ally in healing, not just a battlefield.


Frequently Asked Questions

What are Engineered Living Therapeutics (ELTs)?ELTs are biological systems, typically engineered microbes (like bacteria) or human cells, programmed to perform specific therapeutic functions within the body to treat diseases.

How do ELTs differ from traditional drugs?Unlike static chemical drugs, ELTs are dynamic and can sense the body’s environment, adapt their function, and produce therapeutic effects precisely where and when needed, offering a more intelligent and targeted approach.

What types of diseases can ELTs potentially treat?ELTs show promise across a wide range of conditions, including cancer, autoimmune disorders, metabolic diseases (like diabetes), infectious diseases, and gastrointestinal disorders.

Disclaimer: This article speculates on the potential future applications of cutting-edge scientific research. While based on current scientific understanding, the practical realization of these concepts may vary in timeline and feasibility and are subject to ongoing research and development.

Image credits: Google Gemini

Subscribe to Human-Centered Change & Innovation WeeklySign up here to get Human-Centered Change & Innovation Weekly delivered to your inbox every week.

Why Amazon Paid $3.9 Billion to Get into the Healthcare Business

Why Amazon Paid $3.9 Billion to Get into the Healthcare Business

GUEST POST from Shep Hyken

Amazon is known for its amazing customer experience, despite most customers never talking to an Amazon employee. How does this digital experience — with no human interaction—drive so much loyalty? The short answer is confidence. There is very little that goes wrong with an Amazon experience, and if by chance it does, its system takes care of almost all problems—again, without human interaction. That said, if a customer does need to talk to a human, which is very seldom, the customer support team is there.

But what happens if you combine technology with a high-touch business, like a doctor’s office? You get One Medical, which Amazon bought in 2023 for $3.9 billion. One Medical’s founder, Dr. Tom Lee, is a Harvard-trained primary care physician who then went on to Stanford to get an MBA. Before opening his first clinic, he asked himself, “Why do we do these in healthcare like we’ve always done them? Why does every waiting room look like some sterile IKEA? Why do I wait in a reception area and then wait again in the exam room?” It was questions like these that caused Lee to tinker with and disrupt the traditional medical visit model.

Starting with one clinic, Lee created a different experience. He built an app and charged patients an $89/year subscription that gave them access to doctors. He focused on simple things like getting an appointment without making a call. Those little things were the start of what turned out to be a stellar experience that allowed him to expand, ultimately catching the eye of Amazon.

When the Amazon deal was completed, HealthCare Dive reported that Amazon now had a network of more than 220 medical offices in 27 U.S. markets with more than 836,000 members plus 9,000 enterprise clients. Neil Lindsay, SVP of Amazon Health Services said, “We’re on a mission to make it dramatically easier for people to find, choose, afford and engage with the services, products and professionals they need to get and stay healthy, and coming together with One Medical is a big step on that journey.” That’s what Amazon does. They make it easy for customers.

Joseph Michelli, bestselling business author of numerous books that tell the stories of iconic brands like The Ritz-Carlton, Starbucks, Mercedes and others, recently released a new book, All Business Is Personal: One Medical’s Human-Centered, Technology-Powered Approach to Customer Engagement, that tells the One Medical story. I had a chance to interview him on Amazing Business Radio, and here are the highlights that will give you some insight into why Amazon became interested in acquiring this amazing company.

Question Everything

Just ask, “Why?” It doesn’t matter what type of business you are in, there are reasons for everything. Often the reason a company or person does something is because “We’ve always done it this way.” So, question everything. Maybe you’ll still do it the way you’ve always done it, but at least you will have tried to find a better way.

Create a Stellar Customer (Patient) Experience

As Lee created a Customer Experience (CX) that drove impressive ratings, he looked at the friction most patients experienced. He started with an obvious pain point, the waiting room, which is, as the name implies, a room for people to wait. Some patients in traditional medical practices are forced to wait for unreasonable amounts of time. But not at One Medical. In addition to being easy to get a same-day or next-day appointment, Michelli shared that 95% of patients are seen within three minutes of their scheduled times. As already mentioned, Lee questioned every aspect of the patient’s experience, and he found many ways to make it better.

Blend Technology with the Human Touch

Technology, like apps and AI, makes life more convenient for customers by allowing things like easy online scheduling or getting immediate answers from AI chatbots. Often, technology can feel cold and impersonal, especially in healthcare. The best use of technology is to make things faster and simpler, but smart businesses, like One Medical, know to offer human backup when a customer/patient needs it. Finding the right balance between tech and the human touch keeps your business from being a commodity—just “another faceless service.”

Convenience Is King

People love doing business with companies that create convenient experiences. For One Medical, this means offering same-day appointments, speedy callbacks or handling many issues online versus the phone, so the patient doesn’t have to wait on hold or wait for a callback. Research shows that 73% of customers will pay more for a convenient experience. The easier you make someone’s experience, the more likely they will come back as well as tell others about you.

Make It Personal, Not Just Personalized

It’s great to remember a customer’s name or recall past purchases. That’s personalization. To take it a step further, make it personal. Make the customer feel that you care about them. That means when the customer (or patient) talks to an employee, they feel cared for, listened to and valued. Personal connections build trust and confidence, which leads to repeat business and potential loyalty.

The Effort Is Worth It

These five reasons (and a few more) are what gave Amazon 3.9 billion reasons (as in dollars) to acquire One Medical. Even if you were to practice these reasons flawlessly, you may never catch Amazon’s attention, but you will catch your customers’ (and potential customers’) attention. And that will make the effort worthwhile.

Image Credits: Pixabay

This article originally appeared on Forbes.com

Subscribe to Human-Centered Change & Innovation WeeklySign up here to join 17,000+ leaders getting Human-Centered Change & Innovation Weekly delivered to their inbox every week.

Decoding the Code of Life

Human-Centered Innovation in Synthetic Biology

Decoding the Code of Life

GUEST POST from Art Inteligencia

From my vantage point here in Seattle, I’m constantly tracking emerging technologies that hold the potential to reshape our world. One area that consistently sparks my interest, and demands a strong human-centered lens, is synthetic biology. This revolutionary field combines biology and engineering principles to design and build new biological parts, devices, and systems—essentially allowing us to program life itself. While the possibilities are immense, so too are the ethical and societal considerations, making a human-centered approach to its innovation crucial.

Synthetic biology stands at the intersection of several scientific disciplines, leveraging our increasing understanding of genomics, molecular biology, and genetic engineering. It moves beyond simply reading the code of life to actively writing and rewriting it. This capability opens doors to addressing some of humanity’s most pressing challenges, from developing new medicines and sustainable fuels to creating novel materials and revolutionizing agriculture. However, as we gain the power to manipulate the fundamental building blocks of life, we must ensure that our innovation is guided by ethical principles, societal needs, and a deep understanding of the potential consequences.

A human-centered approach to innovation in synthetic biology means prioritizing the well-being of individuals and the planet. It involves engaging with the public to understand their concerns and aspirations, fostering transparency in research and development, and proactively addressing potential risks. It requires us to ask not just “can we do this?” but “should we do this?” and “what are the potential impacts on human health, the environment, and the fabric of society?” This proactive ethical framework is essential for building trust and ensuring that the transformative potential of synthetic biology is harnessed responsibly and for the benefit of all.

Case Study 1: Engineering Microbes for Sustainable Fuel Production

The Challenge: Dependence on Fossil Fuels and Climate Change

Our current reliance on fossil fuels is a major driver of climate change and environmental degradation. Finding sustainable and renewable alternatives is a critical global challenge. Synthetic biology offers a promising pathway by enabling the engineering of microorganisms to produce biofuels from renewable resources, such as agricultural waste or even captured carbon dioxide.

The Innovation:

Companies and research labs are now engineering yeast and algae to efficiently convert sugars and other feedstocks into biofuels like ethanol, butanol, and even advanced hydrocarbons that can directly replace gasoline or jet fuel. This involves designing new metabolic pathways within these organisms, optimizing their growth conditions, and scaling up production in bioreactors. The human-centered aspect here lies in the potential to create a cleaner, more sustainable energy future, reducing our carbon footprint and mitigating the impacts of climate change. Furthermore, these bioproduction processes can potentially utilize waste streams, contributing to a more circular economy.

The Potential Impact:

Successful development and deployment of these bio-based fuels could significantly reduce our dependence on finite fossil fuel reserves and lower greenhouse gas emissions. Imagine fueling our cars and airplanes with fuels produced by engineered microbes, utilizing resources that would otherwise go to waste. This innovation has the potential to create new jobs in biorefineries and contribute to energy independence, while simultaneously addressing a critical environmental need. However, careful consideration of land use, water resources, and the potential for unintended environmental consequences is paramount to ensure a truly sustainable solution.

Key Insight: Synthetic biology offers powerful tools to engineer sustainable solutions to global challenges like climate change, but a human-centered approach requires careful consideration of the entire lifecycle and potential impacts.

Case Study 2: Cell-Based Agriculture for a Sustainable Food System

The Challenge: Environmental Impact and Ethical Concerns of Traditional Animal Agriculture

Traditional animal agriculture has a significant environmental footprint, contributing to deforestation, greenhouse gas emissions, and water pollution. It also raises ethical concerns about animal welfare. Synthetic biology is paving the way for cell-based agriculture, where meat and other animal products are grown directly from animal cells in a lab, without the need to raise and slaughter animals.

The Innovation:

Companies are now developing methods to cultivate animal cells in bioreactors, providing them with the necessary nutrients and growth factors to proliferate and differentiate into muscle tissue, fat, and other components of meat. This “cultured meat” has the potential to drastically reduce the environmental impact associated with traditional farming and address ethical concerns about animal treatment. From a human-centered perspective, this innovation could lead to a more sustainable and ethical food system, ensuring food security for a growing global population while minimizing harm to the planet and animals.

The Potential Impact:

Widespread adoption of cell-based agriculture could revolutionize the food industry, offering consumers real meat with a significantly lower environmental footprint. It could also reduce the risk of zoonotic diseases and the need for antibiotics in animal agriculture. However, challenges remain in scaling up production, reducing costs, and gaining consumer acceptance. Addressing public perceptions, ensuring the safety and nutritional value of lab-grown meat, and understanding the potential socio-economic impacts on traditional farming communities are crucial human-centered considerations for this transformative technology.

Key Insight: Synthetic biology can contribute to a more sustainable and ethical food system through cell-based agriculture, but public engagement and careful consideration of societal impacts are essential for its responsible adoption.

Startups and Companies to Watch

The field of synthetic biology is rapidly evolving, with numerous innovative startups and established companies making significant strides. Keep an eye on companies like Ginkgo Bioworks, which is building a platform for organism design; Zymergen, focused on creating novel materials and ingredients through microbial engineering; Impossible Foods and Beyond Meat, leveraging synthetic biology for plant-based and cell-based meat alternatives; Moderna and BioNTech, who utilized mRNA technology (a product of synthetic biology advancements) for their groundbreaking COVID-19 vaccines; and companies like Pivot Bio, developing sustainable microbial fertilizers. This dynamic landscape is constantly generating new solutions and pushing the boundaries of what’s biologically possible.

As we continue to unlock the power of synthetic biology here in America and around the world, it is imperative that we do so with a strong sense of human-centered responsibility. By prioritizing ethics, engaging with society, and focusing on solutions that address fundamental human needs and environmental sustainability, we can ensure that this remarkable technology truly serves the betterment of humanity.

Disclaimer: This article speculates on the potential future applications of cutting-edge scientific research. While based on current scientific understanding, the practical realization of these concepts may vary in timeline and feasibility and are subject to ongoing research and development.

Image credit: Gemini

Subscribe to Human-Centered Change & Innovation WeeklySign up here to get Human-Centered Change & Innovation Weekly delivered to your inbox every week.

Addressing the Veteran Mental Health Crisis

A New Frontier in Healing for Memorial Day Weekend

Addressing the Veteran Mental Health Crisis

by Braden Kelley and Art Inteligencia

As a nation, we have an enduring obligation to the brave individuals who have served in our military. On this Memorial Day weekend, while we honor their sacrifice, we must also look toward a future where we care for the psychological wounds of war. One of the greatest challenges we face is the veteran mental health crisis, with high rates of PTSD, depression, and suicide. Emerging research suggests that psychedelic treatments could significantly alleviate these conditions, providing a new pathway to healing that we cannot afford to ignore.

Understanding the Crisis

The statistics are alarming. According to the Department of Veterans Affairs (VA), approximately 17 veterans die by suicide every day. Furthermore, the VA estimates that around 15% of Vietnam veterans, 12% of Gulf War veterans, and 11-20% of veterans who served in Operations Iraqi Freedom and Enduring Freedom suffer from PTSD in a given year. Traditional treatments like psychotherapy and pharmacotherapy have proven beneficial for some, but many veterans experience symptoms that persist despite these interventions.

The Promise of Psychedelics

In recent years, researchers have turned their attention to the therapeutic potential of psychedelic substances such as MDMA, psilocybin, and LSD. These substances are showing promise in treating PTSD, depression, and other mental health issues. A landmark study conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with the VA found that 67% of participants treated with MDMA-assisted therapy no longer met the diagnostic criteria for PTSD after three sessions. This is a groundbreaking finding that cannot be ignored.

Similarly, psilocybin, the active compound in “magic mushrooms,” has shown potential in alleviating depression and anxiety symptoms in numerous studies. A study from Johns Hopkins Medicine demonstrated that psilocybin-assisted therapy resulted in rapid and sustained reductions in depression severity, with effects lasting for weeks and even months. The therapeutic mechanisms of psychedelics, which include altering neural network connectivity and promoting emotional processing, offer a new realm of possibilities for treatment.

Legal and Regulatory Challenges

Despite promising results, the legal status of these substances remains a significant barrier. Classified as Schedule I substances under the Controlled Substances Act, they are currently deemed to have “no accepted medical use.” However, as the evidence base strengthens, there is growing momentum for reevaluating this classification. States like Oregon and cities such as Denver have decriminalized psilocybin, paving the way for broader acceptance and access.

Building a Comprehensive Support System

To address the veteran mental health crisis effectively, we must take a multi-faceted approach:

  1. Policy Revision and Advocacy: It is crucial for policymakers to prioritize the revision of regulations surrounding psychedelics. We need comprehensive legislative efforts to reclassify these substances, allowing for more extensive research and greater accessibility.
  2. Research and Training: Increased funding for research into psychedelic-assisted therapies is essential. Universities, independent research organizations, and the VA should collaborate to expand clinical trials. Alongside research, training programs for mental health professionals must be developed to ensure they are well-equipped to provide these treatments safely and effectively.
  3. Education and Awareness: Public awareness campaigns can help destigmatize mental health and psychedelic treatments. Stories of healing and recovery should be shared, and educational resources must be made available to veterans, their families, and the general public.
  4. Holistic Care Models: Veteran care must incorporate holistic and integrative approaches, including mindfulness, nutrition, and community support, alongside psychedelic treatments. These support systems are vital for sustaining mental health and can multiply the therapeutic effects of psychedelics.
  5. Veteran-Centric Programs: Programs tailored specifically to veterans’ unique experiences and needs should be developed. Peer support systems, where veterans can share their experiences and support one another through healing, can enhance recovery outcomes.

The Role of Community

Community plays a pivotal role in healing. As a nation, we must foster environments that not only support veterans but actively engage them in the healing process. Community centers focused on veteran well-being, alongside integration programs that help veterans transition back into civilian life with purpose and support, can be transformative.

The Moral Imperative

As we commemorate Memorial Day, we must also reflect on our moral duty to those who have served. The veteran mental health crisis is a call to action—an opportunity not only to acknowledge the sacrifices of our military personnel but to invest in their healing and well-being. Psychedelic treatments represent a beacon of hope, backed by rigorous science and positive outcomes. It is essential for us to come together as a society, to push for changes that reflect our commitment to caring for veterans in the most effective and compassionate ways possible.

Conclusion

The journey to mental health recovery for veterans is not an easy one, but it is a journey we must undertake collectively. By embracing innovation and fostering an environment of openness and support, we can lead the way in addressing the mental health crisis that afflicts our veterans. The time to act is now. With courage, compassion, and collaboration, we can chart a course toward healing and honor the legacy of those who have served with dignity and responsibility.

In the spirit of unity and progress, let us stand together to advocate for effective solutions and a brighter future for all veterans. Their healing is our mission. Let us not falter in this duty.


Accelerate your change and transformation success
Image Credit: Microsoft CoPilot

Content Authenticity Statement: Most of the paragraphs in the article were created with the help of OpenAI Playground.

Subscribe to Human-Centered Change & Innovation WeeklySign up here to get Human-Centered Change & Innovation Weekly delivered to your inbox every week.

The Breakthrough Lifecycle

The Breakthrough Lifecycle

GUEST POST from Greg Satell

Many experts suspect that the COVID crisis is receding into the background. It is, of course, hard to know for sure. There will continue to be debate and we will still need to have some mitigating measures in place. Still, for the most part, people are back at work, kids are in school, and relatively normal routines have returned.

Generations from now, historians will most likely still question what lessons are to be gleaned from the past few years. Should we strengthen our multilateral institutions or have they become so sclerotic that they need to be dismantled? Is the rise of populist nationalism a harbinger for the future or a flash in the pan?

One thing I don’t expect to be hotly debated, in fact seems perfectly clear even now, is that science saved us. Untold thousands, working mostly anonymously in labs around the world, created a vaccine of astonishing efficacy in record time. It is these types of breakthroughs that change the course of history and, if we can embrace their power, lead us to a better future.

A Seemingly Useless Idea

The MRNA technology that led to the Moderna and Pfizer-BioNTech vaccines have the potential to revolutionize medical science. It can rapidly reprogram the machinery in our cells to manufacture things that can potentially cure or prevent a wide range of diseases, from cancer to malaria, vastly more efficiently than anything we’ve ever seen before.

Yet while revolutionary, it is not at all a new idea. In fact Katalin Karikó, who pioneered the approach, published her first paper on mRNA-based therapy way back in 1990. Unfortunately, she wasn’t able to win grants to fund her work and, by 1995, things came to a head. She was told that she could either direct her energies in a different way, or be demoted.

This type of thing is not unusual. Jim Allison, who won the Nobel Prize for his work on cancer immunotherapy, had a very similar experience when he had his breakthrough, despite having already become a prominent leader in the field. “It was depressing,” he told me. “I knew this discovery could make a difference, but nobody wanted to invest in it.”

The truth is that the next big thing always starts out looking like nothing at all. Things that really change the world always arrive out of context for the simple reason that the world hasn’t changed yet.

Overcoming Resistance

Humans tend to see things in a linear fashion. It is easier for us to imagine a clear line of cause and effect, like a row of dominoes falling into each other, rather than a series of complex interactions and feedback loops. So it shouldn’t be surprising that, in hindsight, breakthrough ideas seem so obvious that only the most dim-witted would deny their utility.

When we think of something like, say, electricity, we often just assume that it was immediately adopted and the world simply changed overnight. After all, who could deny the superiority of an efficient electric motor over a big, noisy steam engine? Yet as the economist Paul David explained in a famous paper, it took 40 years for it to really take hold.

There are a few reasons why this is the case. The first is switching costs. A new technology almost always has to replace something that already does the job. Another problem involves establishing a learning curve. People need to figure out how to unlock the potential of the new technology. To bring about any significant change you first have to overcome resistance.

With electricity, the transition happened slowly. It wouldn’t have made sense to immediately tear down steam-powered factories and replace them. At first, only new plants used the electricity. Yet it wasn’t so much the technology itself, but how people learned to use it to re-imagine how factories functioned that unlocked a revolution in productivity gains.

In the case of mRNA technology, no one had seen a mRNA vaccine work, so many favored more traditional methods. Johnson & Johnson and AstraZeneca, for example, used a more traditional DNA-based approach using adenoviruses that was much better understood, rather than take a chance on a newer, unproven approach.

We seem to be at a similar point now with mRNA and other technologies, such as CRISPR. They’ve been proven to be viable, but we really don’t understand them well enough yet to unlock their full potential.

Building Out The Ecosystem

When we look back through history, we see a series of inventions. It seems obvious to us that things like the internal combustion engine and electricity would change the world. Still, as late as 1920, roughly 40 years after they were invented, most American’s lives remained unchanged. For practical purposes, the impact of those two breakthroughs were negligible.

What made the difference wasn’t so much the inventions themselves, but the ecosystems that form around them. For internal combustion engines it took a separate networks to supply oil, to build roads, manufacture cars and ships and so on. For electricity, entire industries based on secondary inventions, such as household appliances and radios, needed to form to fully realize the potential of the underlying technology.

Much of what came after could scarcely have been dreamed of. Who could have seen how transportation would transform retail? Or how communications technologies would revolutionize warfare? Do you really think anybody looked at an IBM mainframe in the 1960s and said, “Gee, this will be a real problem for newspapers some day?”

We can expect something similar to happen with mRNA technology. Once penicillin hit the market in 1946, a “golden age” of antibiotics ensued, resulting in revolutionary new drugs being introduced every year between 1950 and 1970. We’ve seen a similar bonanza in cancer immunotherapies since Jim Allison’s breakthrough.

In marked contrast to Katalin Karikó’s earlier difficulty in winning grants for her work, the floodgates have now opened as pharma companies are now racing to develop mRNA approaches for a myriad of diseases and maladies.

The Paradox Of New Paradigms

The global activist Srdja Popović once told me that when a revolution is successful, it’s difficult to explain the previous order, because it comes to be seen as unbelievable. Just as it’s hard to imagine a world without electricity, internal combustion or antibiotics today, it will be difficult to explain our lives today to future generations.

In much the same way, we cannot understand the future through linear extrapolation. We can, of course, look at today’s breakthroughs in things like artificial intelligence, synthetic biology and quantum computing, but what we don’t see is the second or third order effects, how they will shape societies and how societies will choose to shape them.

Looking at Edison’s lightbulb would tell you nothing about radios, rock music and the counterculture of the 60s, much like taking a ride in Ford’s “Model T” would offer little insight into the suburbs and shopping malls his machine would make possible. Ecosystems are, by definition, chaotic and non-linear.

What is important is that we allow for the unexpected. It was not obvious to anyone that Katalin Karikó could ever get her idea to work, but she shouldn’t have had to risk her career to make a go of it. We’re enormously lucky that she didn’t, as so many others would have, taken an easier path. It is, in the final analysis, that one brave decision that we have to thank for what promises to be brighter days ahead.

All who wander are not lost.

— Article courtesy of the Digital Tonto blog
— Image credits: Pixabay

Subscribe to Human-Centered Change & Innovation WeeklySign up here to join 17,000+ leaders getting Human-Centered Change & Innovation Weekly delivered to their inbox every week.

Innovation or Not – The Microdosing Revolution

Innovation or Not - The Microdosing Revolution

GUEST POST from Art Inteligencia

In recent years, the concept of microdosing has moved from the fringes of alternative therapy into the mainstream as a potential tool for enhancing mental performance and wellness. But is microdosing truly an innovation, or is it a passing trend destined for the annals of speculative practices? Through examining its revolutionary potential and analyzing its impact in real-world scenarios, we can better understand the role microdosing plays in our continuous pursuit of human-centered innovation.

Understanding Microdosing

Microdosing typically involves taking sub-perceptual doses of psychedelics, like LSD or psilocybin, approximately one-tenth of a recreational dose, to experience the potential therapeutic benefits without hallucinogenic effects. Advocates claim it can boost creativity, alleviate anxiety, and improve focus, leading to its rising popularity among entrepreneurs, artists, and the tech-savvy.

Case Study 1: Microdosing in Silicon Valley

In the competitive landscape of Silicon Valley, professionals are constantly seeking a competitive edge to enhance productivity and creativity. The tech hub has notably become a breeding ground for experimentation with microdosing. Tech workers claim the practice helps them to sustain high levels of innovation and problem-solving abilities in an environment where mental agility is highly prized.

For instance, a significant number of software developers and startup founders have reported that microdosing has supported cognitive function and stress reduction, leading to improved workplace performance and job satisfaction. Companies have begun embracing wellness practices, subtly endorsing microdosing as part of a broader strategy to cultivate employee well-being and foster an innovative work culture.

Case Study 2: Microdosing in Mental Health Treatment

Beyond corporate environments, microdosing has gained attention as a potential revolutionary approach in mental health treatment. Psychedelics-assisted therapy research has opened up dialogues about microdosing’s efficacy as a treatment for mood disorders and PTSD. Leading institutions are exploring the controlled use of microdoses as an adjunct to traditional therapies.

A pilot study conducted at a renowned university evaluated the impact of psilocybin microdosing on patients with treatment-resistant depression. Preliminary findings suggest a marked improvement in mood stabilization and cognitive flexibility among participants, renewing hope for alternative approaches in mental health treatment. This study has prompted further research and dialogue within the medical community, transforming discussions around treatment paradigms.

Case Study 3: Brez Beverages – Microdosing in the Consumer Market

Brez Beverages, a pioneering player in the beverage industry, has embraced the microdosing revolution by developing a line of drinks infused with adaptogenic and nootropic compounds. Their products aim to provide consumers with the benefits of microdosing in a more accessible and socially acceptable format.

Brez Beverages

The innovative approach of Brez Beverages lies in their ability to tap into the growing desire for wellness-centric consumer products. By integrating microdosed elements into beverages, they offer a unique alternative for individuals seeking mental clarity and stress reduction without committing to psychedelic substances. Brez Beverages represents a shift in how microdosing concepts can be commercialized and introduced to mainstream consumers.

Market feedback indicates a burgeoning interest among health-conscious customers who are drawn to the idea of enhancing their daily lives with subtle botanical blends, thus carving a new niche in the health and wellness sector. Brez continues to capitalize on the demand for unconventional health solutions, reflecting both the challenge and potential of integrating microdosing into consumer products.

The Verdict: Innovation or Not?

Whether microdosing is labeled as an innovation largely depends on one’s perspective. On one hand, it presents a novel application of existing compounds, showcasing unconventional problem-solving in enhancing human potential—an experimental departure from typical wellness and therapeutic practices. On the other hand, its lack of universal acceptance and scientific consensus makes it a contentious archetype of modern self-experimentation rather than unmistakable innovation.

In conclusion, microdosing embodies the dynamic nature of innovation—provocative yet promising. As we push the boundaries of what’s possible in the human experience, microdosing remains an emblem of the desire to enhance and evolve our capabilities. Whether it stands the test of time will depend on ongoing research, legal structures, and societal acceptance, but it undoubtedly shapes the current discourse on potential pathways for human-centered transformation.

Image credit: DrinkBrez.com, Pexels

Subscribe to Human-Centered Change & Innovation WeeklySign up here to get Human-Centered Change & Innovation Weekly delivered to your inbox every week.

Trends in Medical School Innovation and Entrepreneurship Education

Trends in Medical School Innovation and Entrepreneurship Education

GUEST POST from Arlen Meyers, M.D.

Biomedical and health entrepreneurship continues to expand around the world. Driven by global pressures to optimize the allocation of scarce resources, life science bioentrepreneurs are creating innovative products, platforms, service and systems that deliver more value. As a result, the demand for biomedical and health professional entrepreneurial talent has increased and biomedical and health innovation and entrepreneurship education and training (BEET) programs are growing to fill the gap.

Authors of a 2019 analysis of 171 allopathic medical schools conducted an exhaustive search of the published literature and websites of existing medical school innovation and entrepreneurship (MS I&E) programs, with an emphasis on answering the following three questions:

1. How are I&E programs organized and integrated with the medical school curriculum?
2. What are the core competencies of the I&E program?
3. How are the core competencies measured/evaluated?

Twenty-eight I&E-oriented medical education programs were identified from 26 schools; all of the programs integrated faculty leadership with backgrounds in medicine, engineering, and/or business/entrepreneurship. Of the programs, 57% (16/28) had been launched within the past four years and 75% (21/28) based program enrollment on a selective application process. Nearly all (27/28) incorporated lecture series and/or hands-on modules as a teaching technique. The most prevalent metric was completion of a capstone project (22/28; 79%). At least 15.2% (26/171) of American and Canadian allopathic medical schools include the option for students to participate in an I&E curriculum-based program.

In a few short years, educational offerings in MS I&E have accelerated, in part due to the impact of the COVID pandemic. Trends include:

  1. Sharing lessons learned teaching medical students innovation and entrepreneurship
  2. Experimenting with various program business models
  3. Creating medical student entrepreneurs
  4. Rethinking MS I&E
  5. Designing a curriculum map and defining learning objectives, entrustable professional activities and knowledge,skills, abilities and competencies
  6. Mentoring and guiding medical students
  7. Offering non-clinical-career options
  8. Providing exit ramps
  9. Rethinking how we select medical students
  10. Resetting the future of academic medical center work
  11. Using principles of medical education reform and what we should be teaching in MedEd 2030
  12. Training MS I&E faculty
  13. Encouraging interprofessional and transdisciplinary entrepreneurship programs
  14. Integrating premed, medical student and postgraduate programs
  15. Encouraging life-long learning

We should teach innovation, entrepreneurship and the business of medicine in medical schools, not MD/MBA programs. MBE programs are a better option for those interested in getting an idea to a patient.

Here are the many reasons why physician entrepreneurship is important and why we are likely to see more of the international design, development and deployment of MS I&E programs in both allopathic and osteopathic schools as well as other health professional schools, including nursing, pharmacy and public health schools. Ultimately, as a result, patients and sickcare systems will be the beneficiaries and doctors will be better and happier.

Image credit: Pixabay

Subscribe to Human-Centered Change & Innovation WeeklySign up here to get Human-Centered Change & Innovation Weekly delivered to your inbox every week.

Mindfulness for Mavericks

Finding Calm in the Chaos of Innovation

Mindfulness for Mavericks - Finding Calm in the Chaos of Innovation

GUEST POST from Art Inteligencia

The world of the innovator — the Maverick — is inherently chaotic. It is defined by relentless speed, constant pivoting, the terror of the unknown, and the inevitable sting of failure. For too long, we have celebrated the myth of the stressed-out, high-octane leader who fuels breakthrough with sheer exhaustion and adrenaline. But this model is not only unsustainable; it is strategically deficient. Exhausted minds make predictable mistakes, miss subtle signals, and react impulsively. As a human-centered change and innovation thought leader, I argue that the single most powerful, yet overlooked, strategic tool for any innovator is Mindfulness — the non-judgmental awareness of the present moment. Mindfulness is not a “soft” wellness trend; it is the hard skill required to cultivate clarity, enhance resilience, and make smarter, more ethical decisions in the face of constant organizational chaos.

Innovation lives in the space between stimulus and response. When an unexpected challenge arises — a competitor’s sudden move, a prototype failure, or a market rejection — the unmindful leader reacts based on fear, bias, or past trauma. The mindful leader, however, creates a brief, intentional pause. This pause is where wisdom resides. It allows them to observe the emotional surge without being hijacked by it, ensuring that their response is strategic and deliberate, not emotional and reactionary. The capacity to be fully present, focused, and non-reactive is, therefore, the core competitive advantage in any fast-moving market. Calm is the new creativity.

Mindfulness as a Strategic Capability

Embedding mindfulness into the innovation culture is not a matter of employee benefit; it is a strategic imperative that directly impacts your bottom line and your capacity for disruptive thought. Here is why it belongs on the strategy table:

  • Reduces Cognitive Bias: Innovation is plagued by confirmation bias and anchoring bias. Mindfulness trains the brain to observe thoughts, feelings, and assumptions as temporary phenomena, not as absolute truths. This ability to decenter from one’s own immediate judgments is vital for seeing new solutions and avoiding fatal strategic blind spots.
  • Accelerates Resilience: Failure is oxygen for innovation. Mindfulness equips teams to process setbacks faster. By practicing non-judgmental observation, innovators learn to treat failure not as a personal crisis, but as neutral data — a valuable data point that requires analysis, not anguish. This allows for quicker pivots and less wasted time mourning a failed concept.
  • Enhances Deep Listening: Human-centered innovation demands empathy. Mindfulness sharpens our ability to listen—not just to the words being said in a user interview, but to the unspoken emotions, the subtle body language, and the unarticulated needs. This deep listening capability is the raw fuel for breakthrough insights.

“The mind is not a vessel to be filled, but a fire to be stoked. Mindfulness is the bellows that focuses the flame.” — Braden Kelley (author of Stoking Your Innovation Bonfire)


Case Study 1: Google’s Search Inside Yourself (SIY) Program – Institutionalizing Calm

The Challenge:

Even at a place like Google, where technical brilliance is abundant, high pressure, rapid scaling, and information overload were creating burnout and hindering effective cross-functional leadership. The challenge was finding a way to enhance emotional intelligence and focus that was rigorous, scientific, and acceptable to a highly analytical culture.

The Mindfulness Solution:

In 2007, Google launched Search Inside Yourself (SIY), a now-famous program pioneered by engineer Chade-Meng Tan. It was a six-week course designed not just for “wellness,” but explicitly to enhance emotional intelligence, self-awareness, and focus through mindfulness training. The program used neurological data and a practical, secular approach to teach engineers and leaders how to manage stress and respond more skillfully to complex workplace situations. By linking mindfulness directly to measurable outcomes like improved collaboration and reduced conflict, the program integrated it as a strategic leadership tool.

The Human-Centered Result:

SIY proved that institutionalizing mindfulness could be scaled, even in the most demanding tech environments. The program fostered a generation of leaders better equipped to handle ambiguity and lead with empathy. It demonstrated that by training the mind to be calm and present, you directly improve the capacity for high-stakes problem-solving and sustainable innovation—making it a core capability, not a peripheral perk.


Case Study 2: Tactical Mindfulness in High-Stakes Environments – The Intentional Pause

The Challenge:

In fields where chaos is the norm—such as emergency medicine, aviation, or high-level tactical operations—decision-making must be instantaneous, precise, and free of panic. A sudden system failure in a cockpit or a rapid-fire sequence of events in a surgical theater demands peak cognitive performance under immense stress. Traditional training focuses on technical checklists, but often fails to address the cognitive breakdown that occurs when fear takes over.

The Mindfulness Solution:

High-reliability organizations, from Navy SEALs to commercial aviation safety experts, increasingly incorporate elements of Tactical Mindfulness into their training. This is not about long meditation sessions; it is about practicing the Intentional Pause. Techniques like “Box Breathing” or a quick “Sensory Scan” (grounding oneself by noting five things they can hear, see, or feel) are used to rapidly interrupt the panic cycle. This returns the prefrontal cortex—the rational decision-making center—to control. The goal is to maximize the time between the chaotic stimulus (e.g., a warning light) and the response, ensuring the action is deliberate and based on training, not terror.

The Human-Centered Result:

This application of mindfulness strips away any lingering stigma and positions it as a non-negotiable performance multiplier. By cultivating the capacity for calm under fire, these professionals significantly reduce error rates. This translates directly to the innovation world: the ability to execute an intentional pause when a major product launch fails, or a critical pivot is required, ensures the team moves from crisis to calculated action with speed and clarity—the very definition of resilient innovation.


Conclusion: The Ultimate Future-Proofing Skill

Mindfulness is the ultimate tool for FutureHacking. It allows the Maverick to rise above the noise of the market and the internal anxiety of their own ambition, creating the necessary cognitive space to see truly disruptive opportunities. Leaders must recognize that their most powerful asset is the clarity of their team’s attention. By modeling and supporting mindfulness, you are not just offering a pathway to reduced stress; you are building an organization that is inherently more focused, more empathetic, more resilient, and ultimately, more capable of sustainable innovation.

The time has come to stop chasing the next distraction and start prioritizing the depth of your presence. The future of change belongs not to the fastest to react, but to the most skilled at pausing. Find the calm within the chaos, and you will find the answers you seek.

Extra Extra: Futurology is not fortune telling. Futurists use a scientific approach to create their deliverables, but a methodology and tools like those in FutureHacking™ can empower anyone to engage in futurology themselves.

Image credit: Wikimedia Commons

Subscribe to Human-Centered Change & Innovation WeeklySign up here to get Human-Centered Change & Innovation Weekly delivered to your inbox every week.

How COVID-19 Has Exposed Us

How COVID-19 Has Exposed Us

GUEST POST from Greg Satell

The moon landing in 1969 was, in many ways, the high point of the American century. Since then, we’ve been beset by scandals like Watergate, Iran-Contra and two presidential impeachments, mired in never-ending wars that we don’t win, while increasingly encumbered by rising debts and income inequality amid falling productivity growth. Incomes have stagnated while education and healthcare costs have soared.

Yet in an essay written back in February, just before the Covid-19 crisis, Ross Douthat wrote that these apparent woes are actually signs of success. In effect, he argued that we lack major technological breakthroughs because we become so technologically advanced, and we lack economic progress because we’ve become so prosperous.

Even then, it was a strange and somewhat maddening position to take. Why would Douthat, an intelligent and insightful man, write such things? Because he so wanted to believe them that he went in search for facts to support them. Many of us have been doing the same. Yet the Covid-19 crisis has unmasked us and it’s time to start facing up to the truth.

A Failed Market Revolution

In 1954, the eminent economist Paul Samuelson, came across an obscure dissertation written by a French graduate student named Louis Bachelier around the turn of the century. The paper, which anticipated Einstein’s later breakthrough on Brownian motion, declared somewhat innocently that “the mathematical expectation of the speculator is zero.”

Samuelson’s discovery launched a revolution in mathematical finance models based on on Bachelier’s assumption, including the Efficient Market Hypothesis, portfolio theory, the Capital Asset Pricing Model (CAPM) and the Black-Scholes model. The underlying assumption was that markets were rational, and risk could be quantified and managed effectively.

The flaws in these models should have been obvious even at the time and some, including the mathematician Benoit Mandelbrot, pointed out that markets were far more volatile than the financial engineering models predicted. Nevertheless, policymakers chose to ignore the warnings and put their faith in the “magic of the market.”

Probably the biggest failure of market fundamentalism is that, as economist Thomas Philippon points out in his book The Great Reversal, over the past 40 years markets in the United States have become significantly weaker. In a similar vein, a study published in Harvard Business Review that examined 893 industries found that two thirds had become more concentrated.

The truth is that we’ve chosen weaker markets and less competition, which has led to less dynamism and innovation. That’s no accident.

Digital Disruption

In Regional Advantage, AnnaLee Saxenian describes how Silicon Valley replaced Boston’s “Technology Highway” as the center of the digital universe. While Boston was corporate and hierarchical, Silicon Valley was freewheeling and networked. The Silicon Valley ethos was very much the counterculture.

So, it was no accident that when Steve Jobs flew to New York to recruit John Sculley, who was at the time President of Pepsi, to lead Apple he asked him,”Do you want to sell sugar water for the rest of your life, or do you want to come with me and change the world?” The implication being that selling computers was a higher calling than selling soft drinks.

That was nearly 40 years ago and while the Covid-19 crisis has certainly highlighted some benefits of digital technology, such as cheap and effective teleconferencing, it’s also become clear that the digital revolution has largely been a disappointment. Productivity growth, except for a relatively brief period in the late nineties and early aughts, has been depressed since the 1970s.

Compare the iPhone to the breakthroughs of the mid-twentieth century, such as Bell Lab’s transistor, Boeing’s 707 and IBM’s 360 and it becomes clear that while digital technology has done much to disrupt industries, it’s done relatively little to create significant new value, at least in comparison to earlier technologies.

The Uncertain Promise of Globalization

The aftermath of the fall of the Berlin Wall was a time of great optimism. With the Cold War over, books like Francis Fukayama’s The End of History predicted a capitalist, democratic utopia in which free markets would conquer the world making everyone more prosperous. Those that refused to reform would be unable to compete.

While there were genuine achievements, especially in lifting up the world’s poorest, it’s hard to see how globalization has made us significantly better off. In fact, rather than the triumph of freedom, we’ve seen a global rise in populist authoritarian movements, the polar opposite of what intellectuals like Fukayama predicted.

In the United States, the situation has become especially dire. Social mobility and life expectancy in the white working class are declining, while anxiety and depression are rising to epidemic levels. While wages have stagnated, the cost of healthcare and education has soared, squeezing the middle class. Income inequality is at its highest level in 50 years.

So, while it’s true that there have been real benefits from globalization, such as curbing inflation, we’ve done little to mitigate the costs to the average citizen. That didn’t just happen but was the result of choices that we made.

We Need to Choose Resilience and Grand Challenges Over Output and Disruption

The Covid-19 crisis has unmasked us. We thought that markets, technology and globalization would save us, that we could just set up some sensible rules of the road and everything would run on autopilot. That’s clearly untrue. We took short-term profits while ignoring long-term costs, loaded up on debt and hoped for the best.

The current crisis has followed the same pattern. We simply failed to prepare for known risks because it seemed expedient not to. George Bush warned about the possibility of a pandemic as did his Health and Human Services Secretary. Jay Leno mocked them. The Obama administration set up a step-by-step playbook and it was ignored. The long list of failures goes on.

Yet we don’t have to be victims of our failed choices. We can learn to make better ones. After the 1918 Spanish Flu pandemic, we embarked on a 70-year productivity boom. Out of the ashes of World War II, we built a new era of peace and prosperity that was unprecedented in world history. We can do so again. We have that power.

New technologies, under development as we speak, will likely give us the power to cure cancer, create clean energy, save the environment and colonize space. We can rebuild the middle class, usher in a new era of peace and prosperity, increase life expectancy while improving quality of life. These are all things we may be able to achieve in the next decade or two.

Yet those possibilities are merely potential that we can succeed or fail to actualize. We can, as we did after World War II, choose to invest in the future and tackle grand challenges. We can build new infrastructure, spawn new industries and create an educated workforce. Or we can, as we did after the end of the Cold War, choose disruption over construction.

What’s clear is that nothing is inevitable. The digital revolution didn’t have to be a dud. The Great Recession didn’t have to happen. The Covid-19 Pandemic could have been, at the very least, greatly mitigated. We are responsible for the choices we make. Now is the time to shoot for the moon (and Mars), not to grade ourselves on a curve.

— Article courtesy of the Digital Tonto blog
— Image credit: Pixabay

Subscribe to Human-Centered Change & Innovation WeeklySign up here to get Human-Centered Change & Innovation Weekly delivered to your inbox every week.

Why We Need Digital Health Package Inserts

Why We Need Digital Health Package Inserts

GUEST POST from Arlen Meyers, M.D.

The Food and Drug Administration announced new rules for nutrition labels that can go on the front of food packages to indicate that they are “healthy.”

According to one source, a package insert is a document included in the package of a medication that provides information about that drug and its use. For prescription medications, the insert is technical, and provides information for medical professionals about how to prescribe the drug. Package inserts for prescription drugs often include a separate document called a “patient package insert” with information written in plain language intended for the end-user — the person who will take the drug or give the drug to another person, for example a minor. Inserts for over-the-counter medications are also written plainly.

In the US the document is called “prescribing information” or the “package insert” (PI) and layperson’s document is called the patient package insert (PPI). In Europe the technical document is called the “summary of product characteristics” (SmPC) and the document for end-users is called the “patient information leaflet” (PIL) or “package leaflet”.

Given the confusion about 1) which digital health product to prescribe for any given patient, 2) the fact that many products are actually consumer products designated to provide information and education, not diagnosis or treatment, and 3) most are not clinically validated or cost-effective, perhaps it’s time to require package inserts for the prescriber and the patients.

Prescription digital therapeutics is also being added to the therapeutic armementarium and is raising several questions about safety, effectiveness, cost-effectiveness, ROI, reimbursement and regulatory requirements, including whether package inserts should be required, how they should be made available to patients, and what they should include.

What is in a package insert is described and required by the FDA and includes:

  • Clinical pharmacology – tells how the medicine works in the body, how it is absorbed and eliminated, and what its effects are likely to be at various concentrations. May also contain results of various clinical trials (studies) and/or explanations of the medication’s effect on various populations (e.g. children, women, etc.).
  • Indications and usage – uses (indications) for which the drug has been FDA-approved (e.g. migraines, seizures, high blood pressure). Physicians legally can and often do prescribe medicines for purposes not listed in this section (so-called “off-label uses”).
  • Contraindications – lists situations in which the medication should not be used, for example in patients with other medical conditions such as kidney problems or allergies
  • Warnings – covers possible serious side effects that may occur
  • Precautions – explains how to use the medication safely including physical impairments and drug interactions; for example “Do not drink alcohol while taking this medication” or “Do not take this medication if you are currently taking MAOI inhibitors
  • Adverse reactions – lists all side effects observed in all studies of the drug (as opposed to just the dangerous side effects which are separately listed in “Warnings” section)
  • Drug abuse and dependence – provides information regarding whether prolonged use of the medication can cause physical dependence (only included if applicable)
  • Overdosage – gives the results of an overdose and provides recommended action in such cases
  • Dosage and administration – gives recommended dosage(s); may list more than one for different conditions or different patients (e.g., lower dosages for children)
  • How supplied – explains in detail the physical characteristics of the medication including color, shape, markings, etc., and storage information (e.g., “Store between 68 and 78°F “)

Of course, there would need to be some modifications, like:

  1. Safety and efficacy
  2. Cybersecurity risks
  3. Data security
  4. Data , privacy, ownership and transfer rights
  5. Side effects
  6. Designation as a consumer product or a diagnostic or therapeutic device
  7. Generic substitution possibilities
  8. Adverse app reactions
  9. App-app interactions
  10. Compatibility with other drugs or devices

One thing that will not be in the insert will be what all this costs to you or someone else who has to pay for it.

Research shows that “Safety of apps is an emerging public health issue. The available evidence shows that apps pose clinical risks to consumers. Involvement of consumers, regulators, and healthcare professionals in development and testing can improve quality. Additionally, mandatory reporting of safety concerns is needed to improve outcomes.”

It is short-sighted, however, to let DTC medical apps slip under the regulatory radar. As described in a recent article for Nature, they could turn out to have costs which insurers or taxpayers might ultimately be responsible for.

But, the FDA is not the only agency with regulatory power. How about the Federal Trade Commission? Almost every promotion these days claims “AI-powered” What should be the truth in advertising standards to make that claim? Should there be something like a nutrition label ?

Medical student and resident education in clinical informatics, including artificial intelligence, is a good start. Here are some potential curricular and extracurricular learning opportunities for artificial intelligence in medicine.

At this point you are probably thinking, “We have enough regulations and we love our APPs. So what if they don’t make us any better.”

Go shove your insert.

Next, you’ll be telling us it has to have all that cotton in the bottle too.

Image Credits:

Subscribe to Human-Centered Change & Innovation WeeklySign up here to get Human-Centered Change & Innovation Weekly delivered to your inbox every week.